SAN DIEGO, March 2, 2006 /PRNewswire-FirstCall via COMTEX News Network/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it will present at thefollowing investor conferences:
- The 5th Annual JMP Securities Research Conference on Wednesday,March 8, 2006, at 8:40 a.m. Pacific Time at The Ritz-Carlton in SanFrancisco.
- The SG Cowen & Co. 26th Annual Health Care Conference on Thursday,March 9, 2006, at 8:50 a.m. Eastern Time at The Boston Marriott CopleyPlace in Boston.
Live webcasts of these presentations will be accessible on the company'swebsite, www.acadia-pharm.com, under the investors section and an archivedrecording will be available on the website through March 23, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for CNSdisorders. ACADIA currently has four drug programs in clinical development aswell as a portfolio of preclinical and discovery assets directed at largeunmet medical needs, including schizophrenia, Parkinson's disease, neuropathicpain, and glaucoma. All of the drug candidates in ACADIA's product pipelineemanate from discoveries made using its proprietary drug discovery platform.ACADIA's corporate headquarters is located in San Diego, California and itmaintains research and development operations in both San Diego and Malmo,Sweden.
Contacts:ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Director, Investor RelationsThomas H. Aasen, Vice President and Chief Financial Officer(858) 558-2871